Close Menu
InfoQuest Network
  • News
  • World
    • United States
    • Canada
    • Europe
    • Asia
    • Latin America
    • Australia
    • Africa
  • Politics
  • Business
    • Personal Finance
    • Finance
    • Markets
    • Startup
    • Investing
    • Innovation
    • Billionaires
    • Crypto
  • Tech
  • Lifestyle
  • Sports
  • Travel
  • More
    • Science
    • Entertainment
    • Health & Wellness
    • Immigration
Trending

Michelle Wie West Speaks on Golfer’s Mental Health Concerns in Recent Statement

July 6, 2025

Drones Detect Sharks, Leading to Beach Closures in New York

July 6, 2025

Top VPNs for iPhone in 2025: On-the-Go Privacy Protection

July 6, 2025
Facebook X (Twitter) Instagram
Smiley face Weather     Live Markets
  • Newsletter
  • Advertise
Facebook X (Twitter) Instagram YouTube
InfoQuest Network
  • News
  • World
    • United States
    • Canada
    • Europe
    • Asia
    • Latin America
    • Australia
    • Africa
  • Politics
  • Business
    • Personal Finance
    • Finance
    • Markets
    • Startup
    • Investing
    • Innovation
    • Billionaires
    • Crypto
  • Tech
  • Lifestyle
  • Sports
  • Travel
  • More
    • Science
    • Entertainment
    • Health & Wellness
    • Immigration
InfoQuest Network
  • News
  • World
  • Politics
  • Business
  • Finance
  • Entertainment
  • Health & Wellness
  • Lifestyle
  • Technology
  • Travel
  • Sports
  • Personal Finance
  • Billionaires
  • Crypto
  • Innovation
  • Investing
  • Markets
  • Startup
  • Immigration
  • Science
Home»Business»Markets»Is Johnson & Johnson Stock a Good Buy at $155 Following Strong Q2 Performance?
Markets

Is Johnson & Johnson Stock a Good Buy at $155 Following Strong Q2 Performance?

News RoomBy News RoomJuly 23, 20240 ViewsNo Comments3 Mins Read
Share
Facebook Twitter LinkedIn Pinterest Email Reddit Telegram WhatsApp

Johnson & Johnson (NYSE: JNJ) recently reported its Q2 results, with revenues aligning and earnings exceeding estimates. The company reported revenue of $22.4 billion and adjusted earnings of $2.82 per share, compared to estimates of $22.5 billion and $2.72, respectively. In this note, we discuss Johnson & Johnson’s stock performance, key takeaways from its recent results, and valuation. JNJ stock has seen little change in recent years, moving slightly from levels of $155 in early January 2021 to around $155 now. JNJ underperformed the S&P 500 in 2021 and 2023, with returns of 9% and -11% respectively for the stock, compared to 27% and 24% for the S&P 500 in the same years.

Consistently beating the S&P 500 has been difficult for individual stocks in recent years, even for heavyweights in the Health Care sector and megacap stars. In contrast, the Trefis High Quality Portfolio, with a collection of 30 stocks, has outperformed the S&P 500 each year over the same period. Given the uncertain macroeconomic environment, could JNJ face a similar situation as it did in 2021 and 2023 and underperform the S&P over the next 12 months? From a valuation perspective, JNJ stock looks like it has some room for growth, with an estimated valuation of $172 per share, reflecting around 10% upside from its current levels of $155. JNJ now expects its adjusted earnings per share for 2024 to be in the range of $9.97 and $10.07.

Johnson & Johnson’s revenue of $22.4 billion in Q2 was up 4.3% y-o-y. The company reported a 5.5% rise in Innovative Medicine and a 4.3% growth for its MedTech segment. Excluding the Covid-19 vaccine, pharmaceuticals sales grew 8.8% y-o-y, led by continued market share gains for several drugs. The growth in the MedTech segment can partly be attributed to the higher Electrophysiology sales and Abiomed acquisition. JNJ’s bottom line expanded 10.2% y-o-y to $2.82 on an adjusted basis. JNJ stock hasn’t seen any gains this year, underperforming the broader S&P500 Index, up around 17%.

Kangen Water

Although JNJ faces some challenging macroeconomic factors, higher costs, and patent expiry for Stelara, much of these risks are already priced in. On the positive side, the company’s acquisition of Shockwave Medical will bolster its Cardiovascular sales, and market share gains for new drugs will drive growth for its pharmaceutical business. With JNJ stock trading at 15x forward earnings, there is room for growth from here. It is helpful to see how Johnson & Johnson’s peers fare on metrics that matter. Investors can find valuable comparisons for companies across industries at Peer Comparisons. Johnson & Johnson remains a strong player in the healthcare industry, with potential for growth in the coming years.

Share. Facebook Twitter Pinterest LinkedIn Tumblr Email Reddit Telegram WhatsApp

Related News

Three Dividend Stocks Offering More than 7% Returns in Any Market

August 9, 2024

Reflections on 2008: Navigating a Challenging Economy with Ford

August 9, 2024

Can Baidu’s AI Innovations Drive Stock Growth After Q2 Results?

August 8, 2024

Anticipating the Outcome of Wheaton Precious Metals’ Q2 Results

August 8, 2024

What Factors are Contributing to the Decline in Nintendo Stock Prices?

August 8, 2024

Markets Aiming for Back-to-Back Winning Days

August 8, 2024
Add A Comment
Leave A Reply Cancel Reply

Top News

Drones Detect Sharks, Leading to Beach Closures in New York

July 6, 2025

Top VPNs for iPhone in 2025: On-the-Go Privacy Protection

July 6, 2025

Superquiz: Monday, July 7th

July 6, 2025

Subscribe to Updates

Get the latest news and updates directly to your inbox.

Advertisement
Kangen Water
InfoQuest Network
Facebook X (Twitter) Instagram YouTube
  • Home
  • Privacy Policy
  • Terms of use
  • Press Release
  • Advertise
  • Contact
© 2025 Info Quest Network. All Rights Reserved.

Type above and press Enter to search. Press Esc to cancel.